share_log

Zimmer Biomet Expects Proposed Paragon 28 Transaction To Immediately Accelerate Revenue Growth And To Be Approximately 3% Dilutive To Adjusted EPS In 2025

Zimmer Biomet Expects Proposed Paragon 28 Transaction To Immediately Accelerate Revenue Growth And To Be Approximately 3% Dilutive To Adjusted EPS In 2025

Zimmer Biomet預計擬議的Paragon 28交易將立即加速營業收入增長,並將在2025年對調整後的每股收益產生約3%的稀釋。
Benzinga ·  01/28 23:03

Paragon 28 has announced net revenue for the full year of 2024 to be in a range of $255.9 to $256.2 million, representing 18.2% to 18.4% reported growth over the prior fiscal year.

Paragon 28宣佈2024年全年淨營業收入預期在255.9到25620萬美元的區間,較上一個財政年度報表增長18.2%到18.4%。

Zimmer Biomet expects the proposed transaction, considering the impact of financing, to be approximately 3% dilutive to adjusted earnings per share in 2025, about 1% dilutive to 2026 adjusted earnings per share and accretive to adjusted earnings per share within 24 months of deal close.

Zimmer Biomet預計,考慮到融資的影響,擬議交易將在2025年對調整後的每股收益產生約3%的稀釋影響,2026年約1%的稀釋影響,並將在交易完成後的24個月內對調整後的每股收益產生積極影響。

Zimmer Biomet plans to fund the proposed transaction through a combination of cash on the balance sheet and other available debt financing sources. Zimmer Biomet expects to maintain a strong balance sheet and to continue to support its stated capital allocation priorities.

Zimmer Biomet計劃通過結合資產負債表上的現金和其他可用的債務融資來源來爲擬議交易提供資金。Zimmer Biomet預計將保持強勁的資產負債表,並繼續支持其已確定的資本配置優先事項。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 372

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。